Gujarat Themis Biosyn Share Price Gains Over 10%; To Acquire Sanofi's Anti-TB and Anti-Infective Portfolio for €158 Million

Gujarat Themis Biosyn Limited (GTBL) has announced a significant acquisition of Sanofi's global anti-tuberculosis (TB) and anti-infective portfolio. This strategic move is set to enhance GTBL's presence in the pharmaceutical industry. 

Details of the Acquisition 

On April 23, 2026, GTBL signed an asset purchase agreement to acquire 13 branded generic products from Sanofi.  

These products have a strong market presence in over 55 countries across Europe, the Middle East, and Africa. The portfolio reported net sales of approximately €62 million for the year ending 2025. 

The acquisition includes marketing authorisations, brands, regulatory dossiers, inventory, and associated commercial rights.  

Notably, the transaction does not involve the transfer of manufacturing facilities or employees, making it a capital-efficient and asset-light expansion for GTBL. 

Strategic Implications for GTBL 

This acquisition aligns with GTBL's strategy to strengthen its global pharmaceutical platform and expand its reach in the anti-infective segment.  

By acquiring this portfolio, GTBL gains immediate access to regulated and semi-regulated markets, enhancing its international footprint. 

The move also presents an opportunity for forward integration, allowing GTBL to leverage its existing capabilities in fermentation-based intermediates and active pharmaceutical ingredients (APIs) to support the acquired finished dosage formulations portfolio. 

Financial Aspects of the Deal 

The total consideration for the transaction is €158 million, payable in cash at closing. GTBL plans to fund this acquisition through a mix of debt and equity.  

The transaction is expected to be earnings per share (EPS) accretive, supported by profitable branded generics sales, vertical integration, and improved operating leverage. 

Read More: Enviro Infra Engineers Share Price in Focus; Subsidiary EIE Renewables to Acquire PRA Bihar BESS! 

Gujarat Themis Biosyn Share Price Performance 

As of April 24, 2026, at 11:09 AM, Gujarat Themis Biosyn share price on NSE was trading at ₹358.64 up by 10.55% from the previous closing price. 

Conclusion 

Gujarat Themis Biosyn's acquisition of Sanofi's anti-TB and anti-infective portfolio marks a significant step in its global expansion strategy. By acquiring established brands with clinical relevance, GTBL aims to enhance its market presence and drive growth through lifecycle management and geographic expansion. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing